Relay Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Relay Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $24.25. The average 1-year stock price forecast is 79.36% higher than the current stock price, while the lowest is $18 (+33.14%) and the highest is $32 (+136.69%).

Price Target: $24.25 (+79.36%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18	$24.25	$24	$32
Change	+33.14%	+79.36%	+77.51%	+136.69%

Analyst Ratings

The average analyst rating for Relay Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	10	10	10	10	11	11
Buy	2	2	2	2	2	2
Hold	0	0	0	1	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $13 → $22	Buy	Maintains	$13 → $22	+62.72%	Jun 3, 2026
Chi Meng Fong Bank of America Securities	Bank of America Securities	Buy Maintains $21	Buy	Maintains	$21	+55.33%	Jun 3, 2026
Boris Peaker JonesTrading	JonesTrading	Buy Reiterates $20	Buy	Reiterates	$20	+47.93%	Jun 2, 2026
Yaron Werber TD Cowen	TD Cowen	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 2, 2026
Bradley Canino Guggenheim	Guggenheim	Buy Maintains $22 → $26	Buy	Maintains	$22 → $26	+92.31%	May 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

11.88M

from 15.36M

-22.61%

from 15.36M

Revenue Next Year

19.63M

from 11.88M

65.21%

from 11.88M

EPS This Year

-1.55

from -1.61

EPS Next Year

-1.67

from -1.55

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	3.03M	1.38M	25.55M	10.01M	15.36M	11.88M
Revenue Growth	-96.34%	-54.41%	1,749.82%	-60.83%	53.44%	-22.61%
Gross Profit	-166.36M	-241.62M	-300.84M	-305.43M	-244.15M	10.69M
Gross Margin	-5,492.21%	-17,496.31%	-1,177.64%	-3,052.20%	-1,590.04%	90.00%
Operating Income	-226.11M	-310.95M	-379.42M	-385.67M	-302.74M	-309.41M
Net Income	-363.87M	-290.51M	-341.97M	-337.71M	-276.48M	-291.83M
EPS	-	-	-	-	-1.61	-1.55
Free Cash Flow	-8.17M	-108.60M	-183.52M	-131.63M	-142.71M	-257.83M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	42.0M
Avg	11.9M
Low	3.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	173.5%
Avg	-22.6%
Low	-80.5%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.55
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-